Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?-Reference-Cited by-同舟云学术

Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?

Published:2020-11-16 Issue:1 Volume:30 Page:65-77
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Ingrasciotta Ylenia¹^ORCID,Sultana Janet¹,Formica Dario²,Ientile Valentina¹,Aiello Andrea³,Chinellato Alessandro⁴,Tari Daniele Ugo⁵,Gini Rosa⁶^ORCID,Pastorello Maurizio⁷,Scondotto Salvatore⁸,Cananzi Pasquale⁹,Traversa Giuseppe¹⁰,Rossi Mariangela¹¹,Santoro Domenico¹²,Trifirò Gianluca¹²,

Affiliation:

1. Department of Biomedical and Dental Sciences and Morphofunctional Imaging University of Messina Messina Italy

2. Unit of Clinical Pharmacology, A.O.U. Policlinico “G. Martino” Messina Italy

3. Intexo Società Benefit Milan Italy

4. Pharmaceutical Service, Local Health Authority (ULSS9) Treviso Italy

5. Caserta‐1 Local Health Service Caserta Italy

6. Agenzia Regionale di Sanità della Toscana Florence Italy

7. Department of Pharmacy Palermo Local Health Unit Palermo Italy

8. Department of Epidemiologic Observatory Health Department of Sicily Palermo Italy

9. Sicilian Regional Centre of Pharmacovigilance, Servizio 7‐Farmaceutica, Health Department of Sicily Palermo Italy

10. Pharmacoepidemiology Unit, National Centre for Epidemiology, Italian National Institute of Health Rome Italy

11. Health‐Unit for Pharmaceutical Governance, Umbria Region Perugia Italy

12. UOC Nefrologia e Dialisi, Department of Clinical and Experimental Medicine University Messina Messina Italy

Funder

Università degli Studi di Messina

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5152

Reference47 articles.

1. Prospective management of end‐stage renal failure within a conservative care programme;Dhaun N;BMJ Qual Improv Rep,2013

2. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008‐12 National Health Examination Survey;De Nicola L;Nephrol Dial Transplant,2015

3. The social cost of chronic kidney disease in Italy;Bellelli S;Value Heal,2014

4. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis

5. I costi socio‐sanitari dell'insufficienza renale cronica;Cicchetti A;Farme percorsi Ter,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study;ClinicoEconomics and Outcomes Research;2024-08

2. Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts;Diabetes Therapy;2022-03-15

3. Green Tea Extract Increases Soluble RAGE and Improves Renal Function in Patients with Diabetic Nephropathy;Journal of Medicinal Food;2021-12-01

4. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis;Frontiers in Pharmacology;2021-04-19